Compare Stocks: AAPG, LGND, COGT, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.55 -2.0%	$17.54	$15.02 ▼ $40.47	$1.48B	0.08	6,291 shs	1,460 shs
COGT Cogent Biosciences	$31.41 -3.7%	$36.98	$12.97 ▼ $43.73	$5.66B	0.31	1.76 million shs	2.33 million shs
LGND Ligand Pharmaceuticals	$298.41 0.0%	$290.70	$163.45 ▼ $326.63	$5.95B	1.11	206,147 shs	241,560 shs
PTCT PTC Therapeutics	$62.34 -5.5%	$71.37	$57.74 ▼ $90.87	$5.51B	0.55	1.03 million shs	1.10 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.06%	-0.35%	-6.65%	-7.08%	-58.57%
COGT Cogent Biosciences	+1.97%	-0.34%	-11.16%	-13.06%	+160.83%
LGND Ligand Pharmaceuticals	+2.91%	+7.77%	+4.26%	+4.77%	+74.80%
PTCT PTC Therapeutics	+1.07%	+0.47%	-5.53%	-21.86%	+8.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.55 -2.0%	$17.54	$15.02 ▼ $40.47	$1.48B	0.08	6,291 shs	1,460 shs
COGT Cogent Biosciences	$31.41 -3.7%	$36.98	$12.97 ▼ $43.73	$5.66B	0.31	1.76 million shs	2.33 million shs
LGND Ligand Pharmaceuticals	$298.41 0.0%	$290.70	$163.45 ▼ $326.63	$5.95B	1.11	206,147 shs	241,560 shs
PTCT PTC Therapeutics	$62.34 -5.5%	$71.37	$57.74 ▼ $90.87	$5.51B	0.55	1.03 million shs	1.10 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.06%	-0.35%	-6.65%	-7.08%	-58.57%
COGT Cogent Biosciences	+1.97%	-0.34%	-11.16%	-13.06%	+160.83%
LGND Ligand Pharmaceuticals	+2.91%	+7.77%	+4.26%	+4.77%	+74.80%
PTCT PTC Therapeutics	+1.07%	+0.47%	-5.53%	-21.86%	+8.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	198.67% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	64.14% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.00	12.93% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$99.08	58.94% Upside

Current Analyst Ratings Breakdown

Latest AAPG, LGND, COGT, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/22/2026	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$130.00 ➝ $137.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/16/2026	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
9/15/2026	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
9/14/2026	PTCT PTC Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$98.00
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	17.68	N/A	N/A	$2.04 per share	7.62
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
LGND Ligand Pharmaceuticals	$268.09M	22.20	$7.85 per share	38.01	$51.68 per share	5.77
PTCT PTC Therapeutics	$1.73B	3.01	$8.29 per share	7.52	($2.56) per share	-24.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	777.25	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	31.92	36.04	2.39	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	29.27	2.04	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)

Latest AAPG, LGND, COGT, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
COGT Cogent Biosciences	0.48	13.57	13.57
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
COGT Cogent Biosciences	N/A
LGND Ligand Pharmaceuticals	91.28%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
COGT Cogent Biosciences	6.59%
LGND Ligand Pharmaceuticals	5.60%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
COGT Cogent Biosciences	258	173.52 million	162.09 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

AAPG, LGND, COGT, and PTCT Headlines

Recent News About These Companies

PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 22 at 8:32 AM | finanznachrichten.de

PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4

September 22 at 8:32 AM | rttnews.com

Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00

September 22 at 8:05 AM | marketbeat.com

PTC Therapeutics acquires Fabry disease gene therapy from Sangamo

September 21 at 6:19 PM | streetinsider.com

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21 at 4:30 PM | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $671,200.00 in Stock

September 21 at 4:22 AM | americanbankingnews.com

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

September 20 at 6:35 AM | finance.yahoo.com

PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 10,000 Shares

September 19, 2026 | insidertrades.com

Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT

September 19, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Strong-Buy at Wall Street Zen

September 19, 2026 | americanbankingnews.com

Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy"

September 19, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares

September 18, 2026 | marketbeat.com

PTC Therapeutics, Inc. (PTCT)

September 18, 2026 | finance.yahoo.com

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT

September 15, 2026 | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Analysts

September 15, 2026 | americanbankingnews.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 15, 2026 | marketbeat.com

Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)

September 14, 2026 | marketbeat.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells $678,400.00 in Stock

September 14, 2026 | americanbankingnews.com

Michael Schmertzler Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

September 12, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, LGND, COGT, and PTCT Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$15.54 -0.33 (-2.05%)

Closing price 03:57 PM Eastern

Extended Trading

$15.52 -0.02 (-0.13%)

As of 07:30 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Cogent Biosciences NASDAQ:COGT

$31.41 -1.22 (-3.74%)

Closing price 04:00 PM Eastern

Extended Trading

$31.45 +0.04 (+0.12%)

As of 07:56 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Ligand Pharmaceuticals NASDAQ:LGND

$298.41 -0.09 (-0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$298.50 +0.09 (+0.03%)

As of 07:47 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

PTC Therapeutics NASDAQ:PTCT

$62.34 -3.62 (-5.49%)

Closing price 04:00 PM Eastern

Extended Trading

$63.71 +1.37 (+2.19%)

As of 07:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, LGND, COGT, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, LGND, COGT, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, LGND, COGT, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, LGND, COGT, and PTCT Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Cogent Biosciences NASDAQ:COGT

Ligand Pharmaceuticals NASDAQ:LGND

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, LGND, COGT, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, LGND, COGT, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, LGND, COGT, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, LGND, COGT, and PTCT Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Cogent Biosciences NASDAQ:COGT

Ligand Pharmaceuticals NASDAQ:LGND

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools